"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
| Descriptor ID |
D007376
|
| MeSH Number(s) |
D12.644.276.374.465.021 D12.644.276.374.480.372 D12.776.467.374.465.021 D12.776.467.374.480.372 D23.529.374.465.155 D23.529.374.480.372
|
| Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 7 | 18 |
| 1995 | 16 | 9 | 25 |
| 1996 | 11 | 10 | 21 |
| 1997 | 11 | 7 | 18 |
| 1998 | 10 | 5 | 15 |
| 1999 | 5 | 8 | 13 |
| 2000 | 9 | 10 | 19 |
| 2001 | 11 | 5 | 16 |
| 2002 | 9 | 11 | 20 |
| 2003 | 7 | 11 | 18 |
| 2004 | 5 | 8 | 13 |
| 2005 | 8 | 4 | 12 |
| 2006 | 6 | 6 | 12 |
| 2007 | 7 | 9 | 16 |
| 2008 | 10 | 14 | 24 |
| 2009 | 5 | 11 | 16 |
| 2010 | 4 | 9 | 13 |
| 2011 | 5 | 8 | 13 |
| 2012 | 9 | 7 | 16 |
| 2013 | 3 | 5 | 8 |
| 2014 | 5 | 7 | 12 |
| 2015 | 2 | 4 | 6 |
| 2016 | 7 | 2 | 9 |
| 2017 | 2 | 7 | 9 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 2 | 5 |
| 2020 | 6 | 3 | 9 |
| 2021 | 3 | 1 | 4 |
| 2022 | 6 | 7 | 13 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles.
-
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines. Proc Natl Acad Sci U S A. 2024 Nov 26; 121(48):e2322356121.
-
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 02; 43(1):251.
-
A combined radio-immunotherapy regimen eradicates late-stage tumors in mice. Front Immunol. 2024; 15:1419773.
-
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09). J Clin Oncol. 2024 Aug 10; 42(23):2800-2811.
-
A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus. mBio. 2024 Apr 10; 15(4):e0341323.
-
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
-
Conditional deletion of CD25 in the corneal epithelium reveals sex differences in barrier disruption. Ocul Surf. 2023 Oct; 30:57-72.
-
Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. Clin Cancer Res. 2022 12 01; 28(23):5121-5135.
-
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature. 2022 10; 610(7930):173-181.
-
Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation. Front Immunol. 2022; 13:891925.